Skip to main content

New molecular targets and proof-of-concept therapies for Autism Spectrum Disorders

Project description

Shrinking the autism research gap

Diagnosed before age 3 based on behavioural cues, autism is a major multifactorial neurodevelopmental disorder, affecting 1 in 100 child births worldwide. There is no cure and what is more, there is no one size fits all approach to autism management. The EU-funded THERAUTISM project will aim to shrink the autism research gap to expose the common molecular and cellular dysfunctions underlying autism-related behaviours. It will also investigate the possibility for a safe gene therapy vector – after it takes into account the properties of a new protein function to restore this new target and rescue social deficits in different preclinical models of autism. The aim is to validate new molecular therapeutic targets.

Host institution

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 1 499 025,00
Address
Rue Michel Ange 3
75794 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,00

Beneficiaries (1)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
Net EU contribution
€ 1 499 025,00
Address
Rue Michel Ange 3
75794 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,00